Asset Details
Do you wish to reserve the book?
Thermally enhanced efficacy of chemotherapy potentiates cisplatin-based hyperthermic intraperitoneal chemotherapy in ovarian cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Thermally enhanced efficacy of chemotherapy potentiates cisplatin-based hyperthermic intraperitoneal chemotherapy in ovarian cancer
Do you wish to request the book?
Thermally enhanced efficacy of chemotherapy potentiates cisplatin-based hyperthermic intraperitoneal chemotherapy in ovarian cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Thermally enhanced efficacy of chemotherapy potentiates cisplatin-based hyperthermic intraperitoneal chemotherapy in ovarian cancer
2026
Overview
Ovarian cancer is the deadliest gynecological malignancy, with high relapse and drug resistance rates. Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery and systemic chemotherapy has improved survival in patients with peritoneal metastases, though findings remain inconsistent. This study investigates whether the benefits of HIPEC are due to the additional chemotherapy or the combination with hyperthermia. High-grade and non-high-grade serous ovarian cancer cell lines were treated with carboplatin and paclitaxel. Additionally, the cells were treated with cisplatin at 37 to 43 °C for 90 min (HIPEC). Cell proliferation, colony formation, apoptosis, cell cycle and DNA damage were assessed by MTT, clonogenic assay, flow cytometry, western blot and γ-H2AX foci assay. High-grade serous cells were more sensitive to both carboplatin-paclitaxel and hyperthermia. Cisplatin demonstrated a temperature-dependent synergy with heat, resulting in increased DNA damage, apoptosis, and G2-arrest. Combining carboplatin and paclitaxel with hyperthermia plus cisplatin further reduced survival and increased cellular stress marker compared to carboplatin and paclitaxel alone. Hyperthermia significantly enhances cisplatin efficacy when added to carboplatin and paclitaxel pretreatment. This suggests that the addition of hyperthermia to cisplatin after carboplatin-paclitaxel is more effective than carboplatin-paclitaxel alone in both high-grade and non-high grade serous ovarian cancer.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
Antineoplastic Agents - pharmacology
/ Antineoplastic Combined Chemotherapy Protocols
/ Carboplatin - administration & dosage
/ Cell Proliferation - drug effects
/ Cisplatin - administration & dosage
/ DNA
/ Female
/ Fever
/ Humanities and Social Sciences
/ Humans
/ Hyperthermic intraperitoneal chemotherapy (HIPEC)
/ Hyperthermic Intraperitoneal Chemotherapy - methods
/ Ovarian Neoplasms - drug therapy
/ Ovarian Neoplasms - pathology
/ Paclitaxel - administration & dosage
/ Science
/ Surgery
